peptide elongation factor 2 has been researched along with nelfinavir in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
De Gassart, A; Demaria, O; Gilliet, M; Martinon, F; Panes, R; Ryazanov, AG; Zaffalon, L | 1 |
Campbell, ZT; Kunder, N; Loerch, S; Lou, TF; Smith, PR; Stanowick, AD | 1 |
2 other study(ies) available for peptide elongation factor 2 and nelfinavir
Article | Year |
---|---|
Pharmacological eEF2K activation promotes cell death and inhibits cancer progression.
Topics: AMP-Activated Protein Kinases; Animals; Cell Death; Cell Line; Cell Survival; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance; Elongation Factor 2 Kinase; Female; Gene Expression; Humans; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Knockout; Multiprotein Complexes; Nelfinavir; Neoplasms; Peptide Elongation Factor 2; Phosphorylation; Protein Biosynthesis; TOR Serine-Threonine Kinases; Tumor Burden | 2016 |
Functionally distinct roles for eEF2K in the control of ribosome availability and p-body abundance.
Topics: Animals; Cell Line, Tumor; Cryoelectron Microscopy; Elongation Factor 2 Kinase; Ganglia, Spinal; Humans; Male; Mice; Mice, Knockout; Nelfinavir; Peptide Elongation Factor 2; Phosphorylation; Primary Cell Culture; Processing Bodies; Protein Biosynthesis; Ribosomes; Sensory Receptor Cells | 2021 |